Insightec said today it won Medicare benefit coverage from CGS Medicare and Palmetto GBA for procedures using its Neuravive MR-guided focused ultrasound system to treat essential tremor.
The Israel-based company said that with the addition, 25 states now cover its Neuravive treatment for medication-refractory essential tremor.
“2018 marks the year of Medicare reimbursement for incisionless focused ultrasound treatment for essential tremor. We’re excited by this momentum and look forward to coverage for all Medicare patients in the U.S. in the near future,” board chair and CEO Dr. Maurice Ferré said in a press release.
“Focused ultrasound offers medication-refractory essential tremor patients tremor improvement with no incisions and minimal complications,” Dr. Vibhor Krishna of The Ohio State University Wexner Medical Center said in a press release.
Last week, Insightec said that it won expanded FDA approval for its Exablate Neuro, which is now cleared as compatible with a number of Siemens (NYSE:SI) Healthineer’s magnetic resonance imaging scanners.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.